Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Israel

European Research Council grant · Finished

PepZoPower Novel bio-inspired energy harvesting and storage all-in-one platform for implantable devices based on peptide nanotechnology

Coordinator
Tel Aviv University, Israel
Runs
1 December 2022 to 30 November 2024
Status
Finished
EU funding
€150k
Total cost
—
Partners
2 organisations in 2 countries
Type
European Research Council grant
Grant agreement
101101071

What the project is doing

In the project's own words, from its summary on CORDIS.

Over the past decades, implantable biomedical systems have greatly advanced, offering previously unavailable therapeutic options for millions of patients worldwide. Such applications most commonly utilize conventional lithium-ion batteries as the energy source. However, while readily providing adequate energetic performance, lithium-ion batteries are inflexible, rigid, may contain toxic substances, and require periodic replacement surgeries due to their limited capacity, posing both health risks and an economical burden.

Here, aiming to address these issues, we will develop PepZoPower, a biocompatible energy harvesting, and storage device designed for biomedical applications. Energy harvesting will be facilitated by highly-efficient piezoelectric peptide-based assemblies allowing to harvest mechanical energy from the human body and convert it into electric energy. The harvested mechanical energy will be stored by a biocompatible peptide-based supercapacitor, thus giving rise to an autonomous, miniaturized, controllable, and biocompatible power device with adequate performance and mechanical properties.

This ambitious goal will be achieved by utilizing our patent-protected piezoelectric and energy storage peptide-based supramolecular structures, to be incorporated into an integrated device. The performance of each layer will be optimized and the integrated PepZoPower device will be validated to verify efficient incorporation of the two components. We envision the breakthrough PepZoPower technology to serve as the basis for the next leap toward biocompatible, soft, miniaturized, light-weight and morphologically-controllable implantable devices.

This will pave the way towards post-project commercial exploitation of the PepZoPower system, which will be further developed by a spin-off company to be integrated into implantable devices ranging from cardiac defibrillators to spinal cords stimulators, opening a huge market opportunity for this radically new technology.

Topics

Who is involved

OrganisationCityCountryRole
Tel Aviv UniversityTel AvivIsraelCoordinator
Day One Societa a Responsabilita LimitataRoma RmItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI